Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo

28 Oct 2022

Abstract excerpt

Alzheimer’s disease (AD) is a complex and widespread condition, still not fully understood and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by inhibition of the enzymes BACE-1 (β-secretase) and AChE (acetylcholinesterase) by a single inhibitor may be an effective therapeutic approach, as compared to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36361906
DOI: 10.3390/ijms232113098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In VivoPMID 36361906Read ↗

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s DiseaseSemantic proximity Read ↗

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read ↗

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachSemantic proximity Read ↗

Computational Prioritization of Multi-Target Inhibitors: Explainable QSAR and Docking- Based Discovery of Dual AChE/BACE1 ChemotypesSemantic proximity Read ↗

Identification of new BACE1 inhibitors for treating Alzheimer’s diseaseSemantic proximity Read ↗

Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.Semantic proximity Read ↗

Machine Learning-Enhanced Drug Discovery for BACE1: A Novel Approach to Alzheimer's TherapeuticsSemantic proximity Read ↗

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read ↗

Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic ActivitySemantic proximity Read ↗

A Novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer’s disease by dual inhibition of acetylcholinesterase and inflammationSemantic proximity Read ↗

AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.Semantic proximity Read ↗

African Natural Products for Multitarget-Based Treatment of Alzheimer’s Disease: An In Silico StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.